The expression level of CycG1 (CCNG1) was reduced in bladder cancer, head and neck cancer, and sarcoma relative to normal solid tissue (Supplementary Fig. S9a), whereas CycG2 (CCNG2) expression was reduced in colon cancer, head and neck cancer, and rectal cancer (Supplementary Fig. S9b). This evidence concerns the gene CCNG2 and urinary bladder carcinoma.